Solriamfetol Hydrochloride Patent Expiration
Solriamfetol Hydrochloride is Used for improving wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea through a dosing regimen that includes oral administration of Solriamfetol. It was first introduced by Axsome Malta Ltd
Solriamfetol Hydrochloride Patents
Given below is the list of patents protecting Solriamfetol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sunosi | US11771666 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US11771667 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US11779554 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US11793776 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US11872203 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US11872204 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US12005036 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US12036194 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US12064411 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US12090126 | Methods of administering solriamfetol to lactating women | Dec 30, 2042 | Axsome Malta |
| Sunosi | US10940133 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11160779 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11839598 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11839599 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11850226 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11850227 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11850228 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11857528 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11969404 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11986454 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11986455 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Mar 19, 2040 | Axsome Malta |
| Sunosi | US11560354 | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof | Mar 06, 2039 | Axsome Malta |
| Sunosi | US10912754 | Methods and compositions for treating excessive sleepiness | Jun 01, 2038 | Axsome Malta |
| Sunosi | US10959976 | Methods and compositions for treating excessive sleepiness | Jun 01, 2038 | Axsome Malta |
| Sunosi | US11648232 | Methods and compositions for treating excessive sleepiness | Jun 01, 2038 | Axsome Malta |
| Sunosi | US11865098 | Methods and compositions for treating excessive sleepiness | Jun 01, 2038 | Axsome Malta |
| Sunosi | US10195151 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | Sep 05, 2037 | Axsome Malta |
| Sunosi | US10512609 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | Sep 05, 2037 | Axsome Malta |
| Sunosi | US11439597 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | Sep 05, 2037 | Axsome Malta |
| Sunosi | US11998639 | Formulations of (R)-2-amino-3-phenylpropyl carbamate | Sep 05, 2037 | Axsome Malta |
| Sunosi | US8440715 | Treatment of sleep-wake disorders | Jun 11, 2031 | Axsome Malta |
| Sunosi | US10351517 | Treatment of sleep-wake disorders | Jun 07, 2026 | Axsome Malta |
| Sunosi | US11753368 | Treatment of sleep-wake disorders | Jun 07, 2026 | Axsome Malta |
| Sunosi | US8877806 | Treatment of sleep-wake disorders | Jun 07, 2026 | Axsome Malta |
| Sunosi | US9604917 | Treatment of sleep-wake disorders | Jun 07, 2026 | Axsome Malta |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Solriamfetol Hydrochloride's patents.
Latest Legal Activities on Solriamfetol Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Solriamfetol Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eCofC Notification | 28 May, 2024 | US11969404 |
| Recordation of Patent eCertificate of Correction | 28 May, 2024 | US11969404 |
| Patent eCofC Notification | 28 May, 2024 | US11969404 |
| Email Notification Critical | 28 May, 2024 | US11969404 |
| Mail Patent eCofC Notification | 21 May, 2024 | US11771667 |
| Recordation of Patent eCertificate of Correction | 21 May, 2024 | US11771667 |
| Email Notification Critical | 21 May, 2024 | US11771667 |
| Patent eCofC Notification | 21 May, 2024 | US11771667 |
| Change in Power of Attorney (May Include Associate POA) Critical | 03 May, 2024 | US8877806 |
| Email Notification Critical | 03 May, 2024 | US8877806 |
Solriamfetol Hydrochloride's Family Patents
